Meningococcal ACWY Vaccine
Recommendaons by Age and Risk Factor
footnotes
1. If available, use the same vaccine product for all doses in
the series given to infants, including the booster doses.
2. Seekadviceoflocalpublichealthauthoriestodetermineifvac-
cinaonisrecommended.
3. IfiniangvaccinaonwithMenveoinachildage7through23
months, dose 2 should be given no younger than age 12 months.
4. Ifchildage7through23monthswillenteranendemicareain
less than 3 months, give doses as close as 2 months apart.
5.PersistentdeciencyofcomplementcomponentsC3,C5–C9,
properdin, factor D, or factor H caused by an immune system
disorder or by taking a complement inhibitor (Soliris [eculizumab]
or Ultomiris [ravulizumab]).
6. Ifthepersonhasahistoryof1doseofMenACWYatthemeof
diagnosiswithahigh-riskcondionforwhicha2-doseprimary
series is recommended, give dose 2, then boost every 5 years as
long as risk remains.
Roune Recommendaons for Use of Meningococcal A,C,W,Y Vaccine (MenACWY)
MenACWY Vaccines:
MenACWT-TT(MenQuad;Sano);MenACWY-CRM
(Menveo;GSK)
Risk-based Recommendaons for Persons with Underlying Medical Condions or Other Risk Factors
targeted group by age/or risk factor primary dose(s)
1
booster dose(s)
1
Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic, people present during outbreaks caused by a
vaccine serogroup,
2
and other people with prolonged increased risk for exposure (e.g., microbiologists rounely working with Neisseria meningidis
).
For age 2 through 6 months
Give3dosesofMenveo,8weeksapart,anda4thdose
atage12–18months.
Ifpossible,vaccinaonshould
begin at age 2 months.
Ifprimaryvaccinaoniscompletedbeforethe
7thbirthday:giveoneboosterdose3years
aerprimaryseries,thenevery5yearsthereaf-
ter, as long as risk remains.
Ifprimaryvaccinaoniscompletedatage7
years or older: give a booster dose every 5
yearsthereaer,aslongasriskremains.
Forage7through23monthswhohavenot
iniatedaseriesofMenACWY
Give2-doseseriesofMenveo.
3
Separate the 2 doses by
atleast12weeks.
4
For age 2 years and older Give1doseofanyMenACWYvaccine.
People with persistent complement component deciencies
5
For age 2 through 6 months
Give3dosesofMenveo,8weeksapart,anda4thdose
atage12–18months.Ifpossible,vaccinaonshould
begin at age 2 months.
Ifprimaryvaccinaoniscompletedbeforethe
7thbirthday:giveoneboosterdose3years
aerprimaryseries,thenevery5yearsthereaf-
ter, as long as risk remains.
Ifprimaryvaccinaoniscompletedatage7
years or older: give a booster dose every 5
yearsthereaer,aslongasriskremains.
Forage7through23monthswhohavenot
iniatedaseriesofMenACWY
Give2-doseseriesofMenveo.Separatethe2dosesby
atleast12weeks.
4
For ages 2 years and older
Give2dosesofMenACWY(anyvaccine),8weeks
apart.
6
People with HIV infecon or funconal or anatomic asplenia (including sickle cell disease)
For age 2 through 6 months
Give3dosesofMenveo,8weeksapart,anda4thdose
atage12–18months.Ifpossiblevaccinaonshould
begin at age 2 months.
Ifprimaryvaccinaoniscompletedbefore
the7thbirthday:giveoneboosterdose3
yearsaerprimaryseries,thenevery5years
thereaer.
Ifprimaryvaccinaoniscompletedatage7
years or older: give a booster dose every 5
yearsthereaer.
Forage7through23monthswhohavenot
iniatedaseriesofMenACWY-CRM
Give2dosesofMenveo.
3
Separate the 2 doses by at
least12weeks.
For ages 2 years and older
Give2dosesofMenACWY(anyvaccine),8weeks
apart.
6
This table covers roune vaccinaon of preteens and teens, as well as catch-up vaccinaon of teens and young adults.
age of patient vaccination history recommended menacWy schedule
Age11through12years None Givedose#1ofMenACWY.
Age13through15years None Givecatch-updose#1ofMenACWY.
Age16years 1 prior dose Givedose#2ofMenACWY.
Age16through18years
None Give1doseofMenACWY.
1priordosewhenyoungerthan16yrs Givedose#2ofMenACWY.
Age19through21years None,or1priordosewhenyoungerthan16yrs Considergiving1doseofMenACWY.
First year college students living
in residence halls
None,or1priordosewhenyoungerthan16yrs,or1prior
dose since 16th birthday, but more than 5 yrs previ
o
usly
Give1doseofMenACWY.
Note: AseparatevaccineisneededforproteconagainstmeningococcalserogroupBdisease;acombinaonMenABCWYvaccine(Penbraya,Pzer)isalso
availableifage10yearsorolderandneedingproteconagainstserogroupsA,B,C,W,andY.
FOR PROFESSIONALS www.immunize.org / FOR THE PUBLIC www.vaccineinformation.orgFOR PROFESSIONALS www.immunize.org / FOR THE PUBLIC www.vaccineinformation.org
www.immunize.org/catg.d/p2018.pdf
Item#P2018(1/19/2024)
Scan for PDF
